Triveni Bio launches with $92M Series A to fund eczema antibody treatment
Triveni Bio has raised $92 million in a Series A financing round as it aims to move its atopic dermatitis antibody into the clinic.
Atlas Venture and Cormorant Asset Management led the round, with Massachusetts-based Triveni aiming to move TRIV-509 into the clinic in 2025 and a Phase IIa trial in atopic dermatitis in 2027. It also expects to nominate two other antibody candidates in 2024 that focus on other immunological and inflammatory disorders. The company’s cash runway is now set to last into 2027.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.